The clinical applications of Bone Marrow CD34 Immunohistochemistry (BM CD34 IHC) assays are outlined in the ICSH guidelines. These assays are crucial in hematology for diagnosing and managing various blood disorders, including leukemias and myelodysplastic syndromes. BM CD34 IHC helps in identifying and quantifying CD34-positive cells, which are essential for understanding disease progression and treatment response. This technique is widely recognized for its role in research and clinical practice, aiding in the accurate interpretation of bone marrow biopsies and informing therapeutic decisions. The guidelines ensure standardized approaches, enhancing reliability across diagnostic centers.
Bone Marrow CD34 Immunohistochemistry (BM CD34 IHC) Assay: Clinical Applications According to International Council for Standardization in Hematology (ICSH) Guidelines
The BM CD34 IHC assay is a crucial diagnostic tool in hematology, particularly for evaluating bone marrow samples to assess pathological conditions. According to guidelines established by the International Council for Standardization in Hematology (ICSH), this assay plays a significant role in determining the presence and extent of certain blood disorders, including leukemia and myelodysplastic syndromes. The assay leverages the CD34 antigen, a marker expressed on hematopoietic stem and progenitor cells, to identify and quantify these cells within bone marrow biopsies. This information is vital for staging diseases, monitoring treatment responses, and guiding therapeutic interventions. Adherence to ICSH standards ensures the accuracy and reliability of BM CD34 IHC results, making it an essential method in clinical practice.
